Micro RNA and cancer chemoprevention

Cancer Prevention Research

Volumn 6, Issue 5, 2013, Pages 401-409

  Yi, Bin ^a   Piazza, Gary A ^a   Su, Xiulan ^b   Xi, Yaguang ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALPHA TOCOPHEROL; CALCITRIOL; CELECOXIB; CURCUMIN; ELLAGITANNIN; EPIGALLOCATECHIN GALLATE; FOLIC ACID; FULVESTRANT; GENISTEIN; MICRORNA; OMEGA 3 FATTY ACID; RESVERATROL; RETINOIC ACID; SULINDAC SULFIDE; TAMOXIFEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; ANIMAL; GENETICS; NEOPLASMS; PROGNOSIS; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877259958     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0032     Document Type: Review

References (95)

1. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105.
2. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20. (Pubitemid 40094598)
3. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNAtarget recognition. PLoS Biol 2005; 3:e85.
4. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. Micro RNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-60. (Pubitemid 39472426)
5. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAsby the microprocessor complex. Nature 2004; 432: 231-5. (Pubitemid 39545854)
6. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11:228-34.
7. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404:293-6. (Pubitemid 30163547)
8. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69.
9. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human microRNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem 2005; 280:16635-41. (Pubitemid 41389120)
10. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64:3753-6. (Pubitemid 38697282)
11. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524-9. (Pubitemid 35403967)
12. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005; 102:13944-9. (Pubitemid 41377683)
13. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101:2999-3004. (Pubitemid 38327724)
14. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1-12. (Pubitemid 46096921)
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74.
16. Lee SK, Calin GA. Non-coding RNAs and cancer: new paradigms in oncology. Discov Med 2011; 11:245-54.
17. Negrini M, Nicoloso MS, Calin GA. Micro RNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol 2009; 21: 470-9.
18. Plaisier CL, Pan M, Baliga NS. A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res 2012; 22:2302-14.
19. Ruan K, Fang X, Ouyang G. Micro RNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285:116-26.
20. Ross SA, Davis CD. Micro RNA, nutrition, and cancer prevention. Adv Nutr 2011; 2:472-85.
21. Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 2010; 27:1027-41.
22. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000; 78:199-334.
23. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985; 45: 1-8. (Pubitemid 15196921)
24. Izzotti A, Cartiglia C, Steele VE, De Flora S. Micro RNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res 2012; 751:287-303.
25. Neelakandan K, Babu P, Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr Cancer Drug Targets 2012; 12:716-40.
26. Karius T, Schnekenburger M, Dicato M, Diederich M. Micro RNAs in cancer management and their modulation by dietary agents. Biochem Pharmacol 2012; 83:1591-601.
27. Freemantle SJ, Dragnev KH, Dmitrovsky E. The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst 2006; 98:426-7.
28. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, et al. Micro RNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007; 26: 4148-57. (Pubitemid 46920170)
29. Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene 2009; 28:4034-40.
30. Rossi A, D'Urso OF, Gatto G, Poltronieri P, Ferracin M, Remondelli P, et al. Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4. BMC Res Notes 2010; 3:24.
31. Zhong H, Wang HR, Yang S, Zhong JH, Wang T, Wang C, et al. Targeting Smad4 links microRNA-146a to the TGF-beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line. Int J Hematol 2010; 92:129-35.
32. Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Yin XL, et al. Micro RNA29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood 2012; 119:4992-5004.
33. Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia V, Paroni G, et al. Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J Biol Chem 2011; 286:4027-42.
34. Ulrich CM. Folate and cancer prevention: a closer look at a complex picture. Am J Clin Nutr 2007; 86:271-3. (Pubitemid 47256907)
35. Marsit CJ, Eddy K, Kelsey KT. Micro RNA responses to cellular stress. Cancer Res 2006; 66:10843-8. (Pubitemid 44876980)
36. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99:671-8. (Pubitemid 44521987)
37. Gocek E, Wang X, Liu X, Liu CG, Studzinski GP. Micro RNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of Ara Cinduced apoptosis. Cancer Res 2011; 71:6230-9.
38. Wang X, Gocek E, Liu CG, Studzinski GP. Micro RNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009; 8: 736-41.
39. Peng X, Vaishnav A, Murillo G, Alimirah F, Torres KE, Mehta RG. Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J Cell Biochem 2010; 110:1324-33.
40. Ting HJ, Messing J, Yasmin-Karim S, Lee YF. Identification of microRNA-98 as a Therapeutic Target Inhibiting Prostate Cancer Growth and a Biomarker Induced by Vitamin D. J Biol Chem 2013; 288:1-9.
41. Essa S, Denzer N, Mahlknecht U, Klein R, Collnot EM, Tilgen W, et al. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol 2010; 121: 110-3.
42. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. Micro RNA regulates human vitamin D receptor. Int J Cancer 2009; 125:1328-33.
43. Essa S, Reichrath S, Mahlknecht U, Montenarh M, Vogt T, Reichrath J. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. Anticancer Res 2012; 32:383-9.
44. Alvarez-Diaz S, Valle N, Ferrer-Mayorga G, Lombardia L, Herrera M, Dominguez O, et al. Micro RNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet 2012; 21:2157-65.
45. Yang CS, Suh N, Kong AN. Does vitamin E prevent or promote cancer? Cancer Prev Res 2012; 5:701-5.
46. Gaedicke S, Zhang X, Schmelzer C, Lou Y, Doering F, Frank J, et al. Vitamin E dependent microRNA regulation in rat liver. FEBS Lett 2008; 582:3542-6.
47. Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND, et al. Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res 2004; 64:6797-804. (Pubitemid 39297944)
48. Davidson LA, Wang N, Shah MS, Lupton JR, Ivanov I, Chapkin RS. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 2009; 30: 2077-84.
49. Oyagbemi AA, Saba AB, Ibraheem AO. Curcumin: from food spice to cancer prevention. Asian Pac J Cancer Prev 2009; 10:963-7.
50. Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, Nelson LD, et al. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci Rep 2011; 31:185-97.
51. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008; 7:464-73. (Pubitemid 351482129)
52. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009; 2: 409-18.
53. Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting Jun B and Jun D. Carcinogenesis 2010; 31: 1561-6.
54. Dhar S, Hicks C, Levenson AS. Resveratrol and prostate cancer: promising role for microRNAs. Mol Nutr Food Res 2011; 55:1219-29.
55. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 2008; 32:475-80. (Pubitemid 351200247)
56. Kasimsetty SG, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D. Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 2010; 58:2180-7.
57. Wen XY, Wu SY, Li ZQ, Liu ZQ, Zhang JJ, Wang GF, et al. Ellagitannin (BJA3121), an anti-proliferative natural polyphenol compound, can regulate the expression of MiRNAs in HepG2 cancer cells. Phytother Res 2009; 23:778-84.
58. Ai RT, Wu SY, Wen XY, Xu W, Lv L, Rao JJ, et al. 1,3,4-tri-O-galloyl-6-O- caffeoyl-beta-D-glucopyranose, a new anti-proliferative ellagitannin, regulates the expression of microRNAs in HepG(2) cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31:1641-8.
59. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008; 269:226-42.
60. Sun Q, Cong R, Yan H, Gu H, Zeng Y, Liu N, et al. Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol Rep 2009; 22:563-7.
61. Chen Y, Zaman MS, Deng G, Majid S, Saini S, Liu J, et al. Micro RNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res 2011; 4:76-86.
62. Chakrabarti M, Ai W, Banik NL, Ray SK. Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells. Neurochem Res 2013; 38:420-32.
63. Chakrabarti M, Khandkar M, Banik NL, Ray SK. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res 2012; 1454:1-13.
64. Shen G, Li X, Jia YF, Piazza GA, Xi Y. Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin 2013; 34:336-41.
65. Wang H, Bian S, Yang CS. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 2011; 32:1881-9.
66. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J 2011; 25:1198-207.
67. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2010; 21:140-6.
68. Melkamu T, Zhang X, Tan J, Zeng Y, Kassie F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010; 31:252-8.
69. Li Y, Vanden Boom TG II, Kong D, Wang Z, Ali S, Philip PA, et al. Upregulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69:6704-12.
70. Jin Y, Zou X, Feng X. 3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells. Anticancer Drugs 2010; 21:814-22.
71. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011; 8:706-13.
72. Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and metaanalysis. Eur J Clin Invest 2011; 41:1245-53.
73. Pan X, Wang ZX, Wang R. Micro RNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010; 10:1224-32.
74. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361:766-76.
75. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. Micro RNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283:29897-903.
76. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. Micro RNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283: 31079-86.
77. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 2010; 9:317.
78. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 2005; 239: 27-36. (Pubitemid 40848726)
79. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. Micro RNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30:1082-97.
80. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159:161-6. (Pubitemid 29055104)
81. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002; 53:35-57. (Pubitemid 34177870)
82. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873-84. (Pubitemid 44315980)
83. Mazhar D, Gillmore R, Waxman J. COX and cancer. QJM 2005; 98: 711-8. (Pubitemid 41548548)
84. Saito Y, Suzuki H, Imaeda H, Matsuzaki J, Hirata K, Tsugawa H, et al. The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int J Cancer 2013; 132: 1751-60.
85. Li X, Gao L, Cui Q, Gary BD, Dyess DL, Taylor W, et al. Sulindac inhibits tumor cell invasion by suppressing NF-kappaB-mediated transcription of microRNAs. Oncogene 2012; 31:4979-86.
86. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 2001; 282:671-7.
87. Lee HC, Park IC, Park MJ, An S, Woo SH, Jin HO, et al. Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J Cell Biochem 2005; 94:597-610. (Pubitemid 41420295)
88. Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, et al. Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 2011; 13:131-44.
89. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 2010; 107:8231-6.
90. Huang GL, Zhang XH, Guo GL, Huang KT, Yang KY, Shen X, et al. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 2009; 21:673-9.
91. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28:341-7.
92. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-8. (Pubitemid 47552092)
93. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-56.
94. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. Micro RNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 2010; 29:29.
95. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. Micro RNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18:350-9. (Pubitemid 351333899)